New pill-and-immunotherapy combo tested for advanced lung cancer
Disease control
Terminated
This study tested a new pill (SLC-391) combined with an immunotherapy drug (pembrolizumab) in people with advanced non-small cell lung cancer. The goal was to see if the combination is safe and can slow tumor growth. The study was stopped early, but it aimed to find the best dose…
Phase: PHASE1, PHASE2 • Sponsor: SignalChem Lifesciences Corporation • Aim: Disease control
Last updated Apr 28, 2026 13:02 UTC